Forskning
Udskriv Udskriv
Switch language
Bispebjerg Hospital - en del af Københavns Universitetshospital
Udgivet

Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Dangers of hyperoxia

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. The Adaptive COVID-19 Treatment Trial-1 (ACTT-1) in a real-world population: a comparative observational study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Association between biomarkers of endothelial injury and hypocoagulability in patients with severe sepsis: a prospective study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The incretin effect in critically ill patients: a case-control study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. European legislation impedes critical care research and fails to protect patients' rights

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Extracorporeal Treatment for Gabapentin and Pregabalin Poisoning: Systematic Review and Recommendations From the EXTRIP Workgroup

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Recommendations from the EXTRIP workgroup on extracorporeal treatment for baclofen poisoning

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Adverse effects from selected antidotes commonly used in poisonings

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Scandinavia

    Publikation: Bidrag til bog/antologi/rapportBidrag til bog/antologiUndervisningpeer review

Vis graf over relationer

BACKGROUND: β-adrenergic antagonists (BAAs) are used to treat cardiovascular disease such as ischemic heart disease, congestive heart failure, dysrhythmias, and hypertension. Poisoning from BAAs can lead to severe morbidity and mortality. We aimed to determine the utility of extracorporeal treatments (ECTRs) in BAAs poisoning.

METHODS: We conducted systematic reviews of the literature, screened studies, extracted data, and summarized findings following published EXTRIP methods.

RESULTS: A total of 76 studies (4 in vitro and 2 animal experiments, 1 pharmacokinetic simulation study, 37 pharmacokinetic studies on patients with end-stage kidney disease, and 32 case reports or case series) met inclusion criteria. Toxicokinetic or pharmacokinetic data were available on 334 patients (including 73 for atenolol, 54 for propranolol, and 17 for sotalol). For intermittent hemodialysis, atenolol, nadolol, practolol, and sotalol were assessed as dialyzable; acebutolol, bisoprolol, and metipranolol were assessed as moderately dialyzable; metoprolol and talinolol were considered slightly dialyzable; and betaxolol, carvedilol, labetalol, mepindolol, propranolol, and timolol were considered not dialyzable. Data were available for clinical analysis on 37 BAA poisoned patients (including 9 patients for atenolol, 9 for propranolol, and 9 for sotalol), and no reliable comparison between the ECTR cohort and historical controls treated with standard care alone could be performed. The EXTRIP workgroup recommends against using ECTR for patients severely poisoned with propranolol (strong recommendation, very low quality evidence). The workgroup offered no recommendation for ECTR in patients severely poisoned with atenolol or sotalol because of apparent balance of risks and benefits, except for impaired kidney function in which ECTR is suggested (weak recommendation, very low quality of evidence). Indications for ECTR in patients with impaired kidney function include refractory bradycardia and hypotension for atenolol or sotalol poisoning, and recurrent torsade de pointes for sotalol. Although other BAAs were considered dialyzable, clinical data were too limited to develop recommendations.

CONCLUSIONS: BAAs have different properties affecting their removal by ECTR. The EXTRIP workgroup assessed propranolol as non-dialyzable. Atenolol and sotalol were assessed as dialyzable in patients with kidney impairment, and the workgroup suggests ECTR in patients severely poisoned with these drugs when aforementioned indications are present.

OriginalsprogEngelsk
TidsskriftCritical care (London, England)
Vol/bind25
Udgave nummer1
Sider (fra-til)201
ISSN1466-609X
DOI
StatusUdgivet - 10 jun. 2021

ID: 68504800